OBI Pharma, Inc., a clinical stage oncology company, researches and develops novel therapeutic agents for unmet medical needs against cancer in Taiwan and internationally. The company's pipeline products include Adagloxad simolenin, which is in phase 3 for the treatment of triple-negative breast cancer; OBI-833 that is in phase 2 for the treatment of non-small cell lung cancer; OBI-3424, which has completed phase 2 for the treatment of liver hepatocellular carcinoma and acute lymphocytic leukemia; OBI-992 which is in phase 1 for the treatment of solid tumors; OBI-902 and OBI-904 that are in preclinical stage for the treatment of solid tumors; OBI-999 is a novel first-in-class Antibody Drug Conjugate (ADC) with a proprietary linker technology that provides a consistent Drug-to-Antibody ratio (DAR) for cancer treatment; and BsADC which is in discovery stage for the treatment of solid tumors. It also engages in investing and trading; and manufacture and wholesale of western medicines, as well as research and development of biotechnology. OBI Pharma, Inc. was founded in 2002 and is headquartered in Taipei, Taiwan.
Frequently asked questions
What sector does OBI Pharma (4174) operate in?
OBI Pharma belongs to the Healthcare sector and operates in the Biotechnology industry.
What is OBI Pharma (4174) current stock price?
As of the latest data, OBI Pharma stock price is NT$26.75, with a previous close of NT$26.75.
What is OBI Pharma (4174) current market capitalization?
OBI Pharma market cap is approximately 3.52 billion.
What is OBI Pharma (4174) Earnings Per Share (EPS)?
The trailing EPS is -NT$30.67.
Does OBI Pharma (4174) pay dividends?
No. OBI Pharma does not pay a dividend.
What is OBI Pharma (4174) beta (volatility) score?
OBI Pharma has a beta of 0.098, indicating lower volatility than the overall market.
